Marshall Wace’s Spark Therapeutics ONCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
– Sell
-187,596
Closed -$18.2M – 2277
2019
Q3
$18.2M Buy
187,596
+128,657
+218% +$12.9M 0.14% 169
2019
Q2
$6.03M Buy
58,939
+8,469
+17% +$914K 0.05% 425
2019
Q1
$5.75M Buy
50,470
+47,485
+1,591% +$3.49M 0.05% 426
2018
Q4
$117K Sell
2,985
-38,323
-93% -$1.66M ﹤0.01% 1344
2018
Q3
$2.25M Buy
+41,308
New +$2.82M 0.02% 655
2018
Q1
– Sell
-6,515
Closed -$335K – 685
2017
Q4
$335K Sell
6,515
-9,901
-60% -$711K 0.01% 340
2017
Q3
$1.46M Buy
+16,416
New +$1.25M 0.07% 191
2017
Q1
– Sell
-94,927
Closed -$4.74M – 891
2016
Q4
$4.74M Buy
+94,927
New +$5.09M 0.03% 487
2016
Q2
– Sell
-13,738
Closed -$405K – 1254
2016
Q1
$405K Buy
+13,738
New +$433K ﹤0.01% 884

Marshall Wace's ONCE Position: Q4 2019 in Review

Marshall Wace sold out of Spark Therapeutics (ONCE) in Q4 2019, closing a stake of 187,596 shares — an estimated $18.2M sold.

Marshall Wace first reported a position in ONCE in Q1 2016 and held it in 9 quarters. The position peaked at $18.2M in Q3 2019. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.

  • Marshall Wace reported no remaining Spark Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Marshall Wace sold 187,596 Spark Therapeutics shares in Q4 2019, an estimated $18.2M.
  • Marshall Wace first reported a position in Spark Therapeutics in Q1 2016 and held it in 9 quarters.
  • Marshall Wace's Spark Therapeutics position peaked at $18.2M in Q3 2019.
  • 0 funds tracked by Wall St. Rank held Spark Therapeutics as of Q4 2019.

Based on Marshall Wace's 13F filing for Q4 2019, filed 14 Feb 2020.